Information Provided By: 
Fly News Breaks for April 27, 2017
ALKS
Apr 27, 2017 | 13:46 EDT
JPMorgan analyst Cory Kasimov attributes Alkermes' Q1 miss to "commercial seasonality and pricing." He points out management reiterated 2017 guidance and highlighted that underlying trends for both Aristada and Vivitrol remain strong. The analyst continues to believe the legacy base business, combined with the growth potential of Vivitrol and Aristada and the optionality of the wholly owned late-stage pipeline, offers an "attractive combo" for investors. Kasimov keeps an Overweight rating on Alkermes with a $78 price target.
News For ALKS From the Last 2 Days
There are no results for your query ALKS
